

AD\_\_\_\_\_

Award Number: DAMD17-03-1-0559

**TITLE:** The Tetraspanin Metastasis Suppressor Gene, KAI1/CD82, and the Proto-Oncogene, Her-2/neu, as Molecular Determinants of Metastasis in Breast Cancer Patients

**PRINCIPAL INVESTIGATOR:** Donald P. Lombardi, M.D.

**CONTRACTING ORGANIZATION:** Texas Southwestern Medical Center  
University  
Dallas, Texas 75390-9105

**REPORT DATE:** August 2004

**TYPE OF REPORT:** Annual Summary

**PREPARED FOR:** U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

**DISTRIBUTION STATEMENT:** Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050516 069

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED
	August 2004	Annual Summary (21 Jul 2003 - 20 Jul 2004)
4. TITLE AND SUBTITLE		5. FUNDING NUMBERS
The Tetraspanin Metastasis Suppressor Gene, KAI1/CD82, and the Proto-Oncogene, Her-2/neu, as Molecular Determinants of Metastasis in Breast Cancer Patients		DAMD17-03-1-0559
6. AUTHOR(S)		
Donald P. Lombardi, M.D.		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)		8. PERFORMING ORGANIZATION REPORT NUMBER
Texas Southwestern Medical Center University Dallas, Texas 75390-9105		
E-Mail: Donald.lombard@im.wustl.edu		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)		10. SPONSORING / MONITORING AGENCY REPORT NUMBER
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		

## 11. SUPPLEMENTARY NOTES

### 12a. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for Public Release; Distribution Unlimited

### 12b. DISTRIBUTION CODE

### 13. ABSTRACT (Maximum 200 Words)

The purpose of this research is to demonstrate that gene amplification of *HER-2/neu* is associated with loss of expression of the tetraspanin metastasis suppressor gene, *KAI1/CD82*, in breast cancer cell lines and patients' primary breast tumors. The scope is limited to breast cancer and mechanisms of metastasis.

#### Results

- We identified three cell lines with gene amplification of *HER-2/neu* and negative *KAI1/CD82* expression to serve as model systems and corroborated these results in primary breast tumors.
- We found that *CO-029*, a tetraspanin metastasis promoter gene, was up-regulated in *HER-2/neu* lines.
- We ectopically expressed *HER-2/neu* in MCF-7 cells and demonstrated that over-expression of *HER-2/neu* resulted in loss of expression of *KAI1/CD82*, but increased expression of *CO-029*.
- Finally, we knocked down expression of *HER-2/neu* by RNAi and demonstrated that *KAI1/CD82* levels increased four-fold.

#### Significance

*HER-2/neu* signaling regulates tetraspanin gene expression to promote metastatic potential. This novel mechanism may explain why women with gene amplification of *HER-2/neu* in their breast tumors are at higher risk for metastasis and death. This is the first demonstration of a receptor tyrosine kinase (RTK) that regulates tetraspanin metastasis genes, and this may be the first example of a broader paradigm linking RTK oncogenes to metastasis genes.

14. SUBJECT TERMS	15. NUMBER OF PAGES		
KAI1, CD82, HER-2/neu, tetraspanin, breast cancer, metastasis, metastasis suppressor gene, CO-029, proto-oncogene, EGFR	29		
16. PRICE CODE			
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

## Table of Contents

<b>Cover Page.....</b>	<b>page 1</b>
<b>SF 298.....</b>	<b>page 2</b>
<b>Introduction .....</b>	<b>page 4</b>
<b>Body .....</b>	<b>pages 5-13</b>
<b>Key Research Accomplishments .....</b>	<b>page 14</b>
<b>Reportable Outcomes .....</b>	<b>pages 15-16</b>
<b>Conclusions.....</b>	<b>pages 17-18</b>
<b>References .....</b>	<b>pages 19</b>
<b>Appendices .....</b>	<b>pages 20-29</b>

## Introduction

Subject The gene amplification of *HER-2/neu* (*HER2*) in breast tumors is associated with poor prognosis in women with breast cancer (Slamon 1987). Patients with breast cancer die of metastatic disease, primarily to the liver, lungs, bone, and brain. Tetraspanins are cell membrane proteins that are critical in cellular adhesion/fusion, invasion/penetration, and motility/metastasis (Hemler 2002). Dynamic regulation of cell adhesion, invasion, and motility are vital to cells that have the ability to metastasize. The molecular mechanisms linking p185<sup>erbB2</sup> signaling to increased metastatic potential remain largely elusive, and no one has linked *HER2* to tetraspanin expression. *KAI1/CD82* (*KAI1*) is a tetraspanin metastasis suppressor gene that is expressed in normal breast ductal epithelia (Lombardi, unpublished results). Its expression is down-regulated in the progression of breast cancer (Yang 2000). Transfection of *KAI1* into a lowly *KAI1* expressing breast cancer cell line results in decreased metastasis in a murine xenograft model (Yang 2001). Loss of *KAI1* expression in breast tumors has been correlated with inferior survival proportions in women with breast cancer (Huang 1998). Purpose I hypothesized that women with breast tumors that contain gene amplification of *HER2* are at increased risk of early relapse and death because in a subset of these patients, p185<sup>erbB2</sup> signaling results in the down-regulation of *KAI1*. Scope After I had stated the above hypothesis, my colleague, Joseph Gerdts, M.D., then at the University of Oxford, used gene expression profiling to study regulated genes in *HER2* positive and *HER2* negative primary breast tumors. Among over 5,000 genes and expressed sequence tags (ESTs) analyzed, *KAI1* was the third most down-regulated gene in the *HER2*+ subset, and its expression was reduced by 15-fold (Wilson 2002). In Specific Aim 1 of this proposal, we first used Hamon Cancer Center (HCC) breast cancer cell lines as a model system to validate the microarray data. Second, we wanted to be sure that this inverse relationship existed in primary breast tumor specimens and was not the result of an *in vitro* artifact of cell culture. Therefore, we analyzed protein expression of the antigens by immunohistochemistry (IHC) in archival tumor blocks that corresponded to the cell lines. Third, we used transfection experiments to ask whether over-expression of *HER2* would result in the down-regulation of *KAI1*. We found, as seen below, that not only was this true, but over-expression of *HER2* also resulted in the increased expression of *CO-029*, a tetraspanin metastasis promoter gene. Therefore, at that point, the scope was broadened to include the characterization of *CO-029*, as a possible downstream mediator of *HER2*'s pro-metastatic properties. Fourth, we used RNA interference (RNAi) to study the effects of down-regulation of p185<sup>erbB2</sup> on tetraspanin expression. We reasoned that decreasing *HER2* mRNA would decrease *CO-029* and increase *KAI1* protein levels. Fifth, in the near future (months 8-12 of Specific Aim 1), we will assay for p185<sup>erbB2</sup>, *KAI1*, and *CO-029* protein expression in a large, retrospective, CALGB archival tumor bank. We intend to ask whether high p185<sup>erbB2</sup> and *CO-029* levels and low *KAI1* levels confer a worse survival rate compared to *HER2*-positive tumors that retain high levels of *KAI1* and low *CO-029* levels. The long-term goal of this research, outside the scope of this Physician-Scientist Training Award, is to discover therapies that will alter tetraspanin metastasis gene expression to inhibit the formation of metastasis in women with breast cancer. For example, because *CO-029* is a cell surface protein, we ultimately aim to inhibit its function by developing reagents (antibodies, peptides, etc.) that will inhibit *CO-029*'s pro-metastatic function. The research

conducted in Specific Aim 1 led to the discovery of the *HER-2/neu* – CO-029 link, and will form the basis for future grant submissions.

## BODY

### Statement of Work


#### **The Metastasis Suppressor Gene, *KAI1/CD82*, and the Proto-oncogene, *HER-2/neu*, as Molecular Determinants of Metastasis in Women with Breast Cancer**

Please note that this “Annual Summary” only reflects eight months of laboratory work on Specific Aim 1. I decided to leave the University of Texas Southwestern Medical School and accept a new position at Washington University School of Medicine. Once I did made decision, I was informed by my Research Associate in Dallas that she wanted to transfer to another laboratory for job security reasons. Therefore, this report reflects work performed from July 21<sup>st</sup>, 2003 until March 24<sup>th</sup>, 2004. I have just hired two people in my new laboratory in St. Louis and will be set up shortly to resume experiments.

### **TASK 1 (SPECIFIC AIM 1)**

To demonstrate that gene amplification and over-expression of *HER-2/neu* (*HER2*) is associated with loss of expression of *KAI1/CD82* (*KAI1*) in breast cancer cell lines and patients’ primary breast tumor samples (months 1-24)

- Analysis of expression of *KAI1* and *HER2* in Hamon Cancer Center (HCC) breast cancer cell lines using immunoblot and Northern blot techniques, and Quantitative Real-Time Reverse Transcriptase Polymerase Chain Reaction (QR-T RT-PCR) (months 1-12)



**Figure 1.** Gene amplification of *HER2* is associated with loss of *KAI1* expression in breast cancer cells. HCC1007, 1419, and 2218 have gene amplification of *HER2* (*HER2+*). HCC70, 1187, 1428, and 1937 have one copy of *HER2* gene per chromosome 17q (*HER2* negative). 20 µg protein loaded per lane. Other experiments with adequate protein loading of HCC1419 showed identical *KAI1* expression (data not shown).

### Immunoblot techniques

In three *HER-2/neu* gene amplified HCC breast cell lines, (HCC1007, 1419, and 2218), there was little or no KAI1/CD82 expression detected by immunoblot. These results validate the earlier findings in the gene expression profiling experiment, and lend support to Specific Aim 1. The combination of gene amplification of *HER2* and high p185<sup>erbB2</sup> expression resulted in highly efficient axillary lymph node metastasis rate (59+ LNs/60 LNs excised=98%).

Two cell lines, HCC1569 and HCC1954, retain KAI1/CD82 expression despite having gene amplification of *HER-2/neu* (data not shown). We welcome results that counter our hypothesis because in the clinical arena, results are never (or nearly never) 100%. For example, while gene amplification of *HER2* is associated with increased risk of metastasis, not all women will relapse with *HER2*+ tumors. Perhaps in these tumors, the signaling pathway from *HER2* to KAI1 is abrogated, or, alternatively, the cell compensates successfully to counteract the pro-invasive, pro-metastatic program that *HER2* turns on. Also, we suspect that the degree of gene amplification (gene dosage), and the numbers of cell surface *HER2* receptors may influence the downstream pathways that lead to increasing metastatic potential in the primary tumor.

### Northern blot analysis

We have analyzed approximately half of the *HER2* negative HCC breast cancer cell lines, and have only found one transcript detectable in those lines that express KAI1. We find no evidence of alternative splice variant that has been reported in the literature (Lee 2003). We will complete the remainder of the Northern blot analysis within the first four months of transfer of the Award. However, we will need to analyze the HCC lines for the alternative spliced variant of KAI1 because this form of KAI1 may be pro-invasive and may increase metastatic potential. This spliced-KAI1 variant is important because the protein is present and may not look different on an immunoblot, but it does not function as the wild-type protein does. That is, exon 7 is deleted in the splice variant, and this corresponds to a 28 amino acid region that is located in the distal part of the extracellular domain 2 to the proximal part of the fourth transmembrane domain. Therefore, lateral protein interactions with integrins may be attenuated (Lee 2003). We are planning to look for alternative splice variants of KAI1 in the remainder of the HCC breast cancer cell lines, particularly in the two that retain some level of KAI1 expression (HCC1569 and HCC1954).

QR-T RT-PCR We are currently collaborating with the Matthew Ellis laboratory to design primers that will allow us to measure mRNA levels in the most quantitative manner possible. We plan to measure mRNA and protein levels side-by-side to see if mRNA levels correlate with protein levels. This issue is very important with tetraspanins because they regulate cellular adhesion, invasion, and motility by protein-protein interactions. In the future, the choice between using cDNA or proteomics as tools to assay for tetraspanin expression may depend on whether mRNA levels are reflective of protein levels. We developed primer pairs with the ABI Primer Express software, but will now use BioRad software because the Ellis laboratory has a BioRad QR-T RT-PCR machine.


- Analysis of *HER2* gene amplification in HCC breast cancer cell lines by fluorescent in-situ hybridization (FISH) (months 1-12)

HCC Breast Cancer Cells	IHC Her-2/neu Score	FISH Score
HCC 1599	Negative	1.6
HCC 1937	Negative	1.12
HCC 1806	Negative	0.94
HCC 1954	3+	4.31
HCC 1143	Negative	1.22
HCC 38	Negative	1.07
HCC 202	3+	3.6
HCC 2218	3+	8.27
HCC 2185	2+	Needs more digestion
HCC 2157	Negative	1.03
HCC 1954	3+	4.01
HCC 1187	1+	1.04
HCC 1419	3+	7.41
HCC 712	Negative	0.86
HCC 1569	3+	4.06
HCC 1500	Negative	0.57
HCC 1007	3+	3.7
HCC 1739	Negative	0.81
HCC 1428	Negative to weak 1+	1.07
HCC 70	Negative	1.06

**Table 1.** FISH of HER2 in breast tumor blocks, with corresponding staining for HER2 protein by IHC. IHC scored as negative, 1+, 2+, or 3+. FISH score = # of copies of HER2 gene/17q chromosome. Scores  $\geq 2.0$  = gene amplification.

To be sure that we were testing the gene amplification of- and not merely the overexpression of- *HER-2/neu* in the HCC breast cancer cell lines, we performed FISH on 21 HCC tumors and cell lines. We have quantified the data as # of gene copies of *HER-2/neu* per # of copies of chromosome 17q. In this way, we correct for chromosomal instability and aneuploidy in the cell lines. In the HCC database, we have proven that seven of the 21 breast cancer cell lines have gene amplification of *HER-2/neu* and that 13 do not. HCC2185 expresses 2+ p185<sup>erbB2</sup>, but we need to repeat the FISH to ascertain whether the expression results from amplification of the *HER2* gene or not. The latter 13 tend not to express levels of p185<sup>erbB2</sup> that can be detected by immunoblot techniques.

- Analysis of cyclin D1 expression using immunoblot, Northern blot, and qR-T RT-PCR; signaling molecules in the HER-2 pathway (months 6-12)



**Figure 2.** Immunoblot of HCC breast cancer cell lines with mAb to cyclin D1. 20  $\mu$ g protein /lane. HCC1428 and 2185 are *HER2*-negative. HCC1007, 1008, 1419, 1569, and 1954 are *HER2*-positive (gene amplified).

HCC lines 1007, 1008, and 1419 express cyclin D1 and do not express KAI1. HCC lines 1569 and 1954 do not express cyclin D1, but retain expression of KAI1. This expression pattern may be significant and will be explored in the *HER2* negative lines. HCC1428 and 2185 are used as controls (*HER2* negative). HCC1419 may be useful in animal models for *HER2*+ breast cancer; it expresses high levels of VEGF and could support its own blood supply.



**Figure 3.** Immunoblot of VEGF (A) expression in HCC breast cancer cell lines. HCC1007, 1008, 1419, 1954, and 2218 contain gene amplification of *HER2*. HCC2185 FISH not finalized.

- Analysis of KAI1 and HER2 protein expression in patients' primary breast tumor specimens in HCC Breast Tumor Repository using immunohistochemistry (IHC) techniques (months 6-12)

Surgery Accession #	KAI1 protein	p185 <sup>erbB2</sup>	Corresponding HCC Breast Cell Line
U92-8061	0.9	0.6	HCC 202
92-9115 B7	1.6	0	HCC70
93-20685 C	2.1	0.9	HCC712
94-10691 O	0.2	2.3	HCC1007
94-13862 C	3.2	1.5	HCC1143
94-14675 B	3.5	1.4	HCC1187
94-20149 B	0	0.4	HCC1395
94-20901 A	0	5.0	HCC 1419
95-10118 F	2.8	0.6	HCC1739
95-12700 C	2.4	0	HCC1806
95-2428 U	0	1.4	HCC1500
96-3684 G	2.3	1.6	HCC2157
95-4110 U	3.5	5.2	HCC 1569
96-4303 I	3.5	0	HCC 2185
U96-672 D	1.4	4.8	HCC 2218


**Table 2.** Protein expression of KAI1 and p185<sup>erbB2</sup> in breast tumor samples that correspond to the HCC breast cancer cell lines. p185<sup>erbB2</sup> protein levels were measured using standard techniques (Wang 2002) that are used clinically in surgical specimens. Results of  $\geq 2.0$  reflects gene amplification and over-expression of the protein. The range is between 0.0 and 5.2. The same software was used to quantify KAI1 expression; KAI1 is also a surface membrane protein.

In Table 2, we report the IHC scores of KAI1 and p185<sup>erbB2</sup> protein expression. As a group, these data in the tumor blocks correlate well with those from the HCC cell lines. Formal statistical analysis will be done once all of the data are available. HCC1419 has amplified HER2, over-expression of p185<sup>erbB2</sup>, and negative expression of KAI1. This cell line will be a candidate line for development of a xenograft model in future studies. HCC1569, despite its

gene amplification and over-expression of HER2, retains ample KAI1 expression and will be a useful line to study signal transduction pathways that do not lead to down-regulation of KAI1. Similar findings were observed in HCC1954 (data not shown). Clinical and pathological data are available from these patients and are presented in Table 3.

Cell Line	FISH	p185 <sup>erbB2</sup> IHC	KAI1 IHC	Axillary Lymph Node
HER-2/neu amplified	Score	Score	Score	# mets/# LN Excised
HCC1007	3.7	2.3	0.2	12/12
HCC1419	7.4	5.0	0.0	5/5
HCC1569	4.1	5.2	3.5	4/18
HCC1954	4.3	5.6	3.3	0/27
HCC2218	8.3	4.8	1.4	42/43

The three HCC cell lines with gene amplification of HER-2/neu and low/negative expression of KAI1, HCC1007, 1419, and 2218, have IHC scores from primary breast cancer tumor blocks that approximate the protein expression observed *in vitro*. Moreover, the corresponding patients developed axillary lymph node metastasis rates of 98% (a total of 59 positive nodes/60 nodes excised). For the two lines that retain robust KAI1 expression *in vitro* and *in vivo*, the efficiency of axillary lymph node metastases is markedly less (9%; 4+ mets/45 LN excised). We do not think that it is a coincidence that CO-029 protein expression is virtually the opposite expression of KAI1 in this model system.




**Figure 4.** Immunoblot of CO-029 protein expression in HCC breast cancer cell lines. 20 µg protein/lane. Actin controls show equal loading of protein in each lane (data not shown).

The two lines that have significant amounts of KAI1 protein expressed, HCC1569 and 1954, have no expression of CO-029. These data are supportive of other data in the literature where KAI1 has metastasis suppressor properties, while CO-029 has metastasis promoter properties. The lines with the lowest KAI1 expression, HCC1007, 1008, 1419, and 2218, all express CO-029. HCC1007 is derived from a primary breast tumor, while the HCC1008 was derived from an axillary lymph metastasis from the same patient. We note that CO-029 expression is higher in the metastasis compared with that from the primary tumor. We also note an extra band, which we will need to further characterize (glycosylation variant vs. alternative spliced variant vs. post-translational processing of protein, etc.).

For future studies, we will optimize staining for CO-029 in these primary breast tumors that have been formalin-fixed and paraffin-embedded.


Thus far, we have presented data that support a direct correlation between HER-2 and CO-029 expression and an inverse correlation between HER2 and KAI1 expression. To prove a causal relationship, we turned to transfection experiments.



**Figure 5.** Ectopic Expression of *HER-2/neu* in MCF-7 Cells Increases CO-029 Expression, but Decreases KAI1 Expression. Immunoblot as described above. Neo depicts transfection with the cassette only. Beta-actin is used as protein loading control.


In Figure 5, we show that the transfection and over-expression of HER2 into MCF-7 breast cancer cells results in the 4.4-fold up-regulation of CO-029 and a 2.0 fold reduction in KAI1 expression. This line is not optimal for analyzing KAI1 expression because it expresses very low KAI1 in wild-type cells. This experiment will be repeated in a HER2-negative HCC line that expresses enough KAI1 to be seen on a Western blot.

If the relationships between HER2 and the two tetraspanins are true and consistent, we should be able to obtain opposite results by knocking down HER-2/neu expression.




**Figure 6.** Knock down of  $p185^{\text{erbB}2}$  protein expression using RNAi in MCF-7/HER-2/neu breast cancer cells.

In Figure 6, we show excellent (~85%) knock down of  $p185^{\text{erbB}2}$  protein expression with an RNA interference oligonucleotide directed against HER2 mRNA.



**Figure 7.** Knockdown of *HER-2/neu* expression results in down-regulation of *CO-029* expression in MCF-7/*HER-2/neu* cells.

As predicted, the knock down of  $p185^{\text{erbB}2}$  protein expression by RNAi resulted in the robust down-regulation of *CO-029*, thus demonstrating a direct correlation between the expression levels of the two proteins. We proceeded to test whether *KAI1* expression would be up-regulated using the same technique in another cell line.



**Figure 8.** Loss of *HER-2/neu* Expression by RNAi Results in Up-regulation of *KAI1* Expression in a *HER2*<sup>+</sup> Cell Line. CD9 levels mirror those of beta-actin (not shown). Data subjected to densitometry analysis.

In Figure 8, we show that *KAI1* expression is up-regulated four-fold in HCC1569 breast cancer cells that have had  $p185^{\text{erbB}2}$  expression knocked down. Another tetraspanin metastasis suppressor protein, CD9/MRP-1 is not affected, suggesting specificity to the inverse relationship between HER2 and KAI1.

- Analysis of the activated, tyrosine-phosphorylated (p-Tyr1248) form of HER2 in HCC cell lines and their corresponding primary tumor blocks (months 6-12)

The phosphotyrosine antibody (Thor 2000) did not work in our hands. We will use an alternative assay, using a co-immunoprecipitation with a Santa Cruz mAb, followed by immunoblotting with a phospho-tyrosine antibody (Agus 2002).

ErbB2 will be immunoprecipitated using a monoclonal antibody (Ab-3, Oncogene Sciences, Boston, MA) covalently coupled to an affinity gel (Affi-Prep 10, Bio-Rad, Hercules, CA). 10  $\mu$ L of gel slurry containing ~ 8.5  $\mu$ g of immobilized Ab-3 will be added to each lysate and the samples will be mixed at room temperature for 2 hr. The gels will be collected by centrifugation, washed three times with lysis buffer, mixed with SDS sample buffer, and heated for 2 min in a boiling water bath. Supernatants will be collected and run on the appropriate SDS-PAGE and electroblotted onto appropriate membranes for analysis.

- an analysis of protein expression of KAI1 and HER2 using immunohistochemistry techniques in a large retrospective CALGB database to correlate their expression with clinical endpoints such as time to progression, time to distant metastasis, disease-free survival, and overall survival (months 12-24)

Dr. Matthew Ellis and I are discussing which CALGB database we would like to use for this experiment. We want to study a sufficient number of tumor samples to ask whether HER2 and CO-029 are directly related, and HER2 and KAI1 are inversely related, in primary breast tumors. I will discuss the project with our statistical consultants to make sure that we have the power to detect meaningful differences. Washington University is a member of the CALGB.

## KEY RESEARCH ACCOMPLISHMENTS

- Validation of my initial hypothesis that *HER-2/neu* gene amplification in breast cancer cells results in the down-regulation of the tetraspanin metastasis suppressor gene, *KAI1/CD82*. We found an inverse association of HER2 and KAI1 protein expression in both HCC breast cancer cell lines and tissue specimens.
- Discovery of *CO-029* as a tetraspanin that is directly correlated with *HER2* in these same breast cancer cell lines.
- Demonstration that *HER2* over-expression results in the up-regulation of *CO-029* and the down-regulation of *KAI1* in MCF-7 cells transfected with *HER-2/neu*.
- Showing that the knock-down of *HER2* by RNAi resulted in the down-regulation of *CO-029* protein expression and the up-regulation of *KAI1* expression in HCC1569 cells.

## REPORTABLE OUTCOMES

- Abstracts

AACR-sponsored meeting: Advances in Breast Cancer Research:  
Genetics, Biology, and Clinical Implications  
Huntington Beach, California  
October 8-12, 2003

Title: Gene Amplification of *HER-2/neu* in Breast Cancer Cells Results in Altered  
Tetraspanin Gene Expression to Promote Metastatic Potential  
See Appendix for abstract content

- Presentations

“Molecular Mechanisms of Metastasis in Women with Breast Cancer”  
Advances in Oncology Conference, September 30, 2003  
Washington University School of Medicine  
St. Louis, Missouri

- Funding applied for based on work supported by this award

American Cancer Society Institutional Research Grant, 2004  
Barnes-Jewish Foundation Grant Program, 2004

- Employment or Research Opportunities Applied for and/or received based on  
Experience/Training supported by this award:

Offered and accepted a faculty position as:  
Assistant Professor of Medicine  
Division of Oncology, Section of Medical Oncology  
Washington University School of Medicine  
May 17<sup>th</sup>, 2004

Member, Siteman Cancer Center  
Member, Breast Cancer Research Program, Matthew Ellis, M.D., Ph.D., Director

- Development of cell lines

The work performed thus far adds to the biochemical classification of the HCC breast cancer cell lines. These lines have been deposited into the ATCC repository and are available to the scientific community. For our own future work, the characterization of these lines is a prelude to our development of xenograft models for these cell lines.

- Informatics such as databases and animal models

Based on the work performed thus far, we will soon attempt to grow the HCC breast cancer cell lines in murine mammary glands to make new and improved xenograft mouse models for human breast cancer. We will apply for funding within the

National Cancer Institute (NCI) Alliance for Nanotechnology in Cancer. Washington University will make an application for a "Nanotechnology Center of Excellence" on March 1<sup>st</sup>, 2005. The principal investigator, Samuel A. Wickline, M.D., is excited about our model system and has invited me to submit a proposal for the overall grant. His laboratory, in collaboration with Greg Lanza, M.D., Ph.D., works on detection of angiogenesis using nanotechnology and molecular imaging tools. They are very interested in collaborating with me on the establishment of xenograft models of breast cancer. Using their expertise in nanotechnology and molecular imaging, we would explore: interactions between tumor cells and blood vessels *in vivo*; early detection of metastasis *in vivo*; interactions of integrin alpha v beta 3 on tumor microvasculature and tetraspanin expression in tumor cells and on tumor microvasculature (tetraspanins bind to and modulate integrin function; Yanez-Mo 2000; Berditchevski 2001; ); imaging platelets *in vivo* and their binding to tumor cells: effects of metastatic cell survival in the circulation.

#### The ER-negative, PR-negative, HER-2/neu-negative breast cancer cell phenotype

At Washington University, the Breast Cancer Research Group is going to apply for an AVON-NCI grant in March 2005. One project will address the urgent need to understand the ER- PR- HER-2/neu – phenotype of breast tumors that behave very aggressively in women with breast cancer. Nine of our HCC cell lines have this "triple negative phenotype" and should provide good models for understanding DNA repair (with Simon Powell, new Chairman of the Department of Radiation Therapy), chemoresistance, metastatic potential, etc.

#### Circulating Tumor Cells

The second focus of the grant will be on circulating tumor cells. We want to set up an animal model system for metastatic breast cancer where we procure breast cells from normal breast ductal epithelia, primary breast tumor, circulating tumor cells, axillary lymph node metastases, and distant metastases. The central question in metastasis research is whether the metastatic potential of a breast tumor is hard-wired into the majority of the primary breast tumor cells or whether only a few of these cells have acquired the ability to spread in the evolution of the primary tumor. We are currently comparing different methodologies for the detection of circulating tumor cells in animal models and in patients as well. One company, Miltenyi Biotec (from Germany) is helping us evaluate magnetic cell sorting technologies and linking them to a flow cytometer that they are unveiling in December 2004.

## CONCLUSIONS

In summary, the work completed for this Award has identified several HCC breast cancer cell lines that can serve as model systems to study the signal transduction pathways that lead from amplified and activated p185<sup>erbB2</sup> receptors to the regulation of tetraspanin gene expression. We have not only verified the findings from a previous microarray experiment (Wilson 2002), but we have discovered that the tetraspanin gene, *CO-029* is up-regulated in *HER-2/neu* gene amplified cells. *CO-029* is the only tetraspanin that is positively correlated with metastasis. *In vitro*, *CO-029* decreases cellular adhesion and increases invasion and motility. *In vivo*, *CO-029* increases metastases and is associated with a consumptive coagulopathy in a rat pancreatic carcinoma model. We found that *CO-029* expression is higher in the matched axillary lymph node metastasis line, HCC1008 compared with that of the primary breast carcinoma cell line, HCC1007.

The implication is that the proto-oncogene and receptor tyrosine kinase, *HER-2/neu*, and its signaling lead to a pro-metastatic phenotype in a subset of breast tumors that have gene amplification of *HER2*. Increased p185<sup>erbB2</sup> signaling led to the increased expression of the tetraspanin metastasis promoter, *CO-029*, and the down-regulation of the tetraspanin metastasis suppressor, *KAI1/CD82*. Future work on this project will now include an emphasis on *CO-029* in parallel with *KAI1*.

Since *CO-029* is expressed more highly in metastatic tumors than in primary tumors, we may be able to target the protein to try to inhibit the formation or further spreading of metastatic disease. It is easier to knock down function of a positive regulator than it is to develop strategies that will up-regulate the expression of a suppressor (such as *KAI1*). We have an antibody to *CO-029* and will test it to see if has inhibitory properties. In the future, we will collaborate with our Antibody/Hybridoma Core Facility to make new antibodies or peptides that inhibit *CO-029* associations.

### "So What"

The identification of *CO-029* as a tetraspanin metastasis gene may lead to therapeutics that would attempt to down-modulate the protein's function as a metastasis promoter.

Monoclonal antibodies or small peptide molecules could be made to inhibit the:

- spreading of established metastases
- metastatic spread of breast cancer following definitive local therapy
- metastatic rate in *HER2+* breast cancer.

In patients with breast cancer, if the combination of *HER2* gene amplification, high *CO-029* expression, and low *KAI1* expression is associated with an even worse prognosis than that for all *HER2+* tumors, then novel treatment strategies could be designed to rationally tailor more aggressive therapy.

At a more basic science level, these findings could lead to:

- the identification of promoter sequences that *KAI1* and *CO-029* have in common that are targets of transcription factors that regulate tetraspanin gene expression.

- the identification of protein-protein interactions, such as tetraspanin-tetraspanin, tetraspanin-integrin, tetraspanin-erbB family members that further our understanding of cellular adhesion, invasion, and motility. These three properties are altered in the epithelial to mesenchymal transition that accompanies the acquisition of metastatic potential.

## References

Agus DB, et al. Targeting ligand-activated erbB2 signaling inhibits breast and prostate tumor growth. *Cancer Cell* 2002; 2: 127-37.

Berditchevski F. Complexes of tetraspanins with integrins: more than meets the eye. *Journal of Cell Science* 114: 4143-51.

Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. *Annual Review of Cell and Developmental Biology* 2003; 19: 397-422.

Huang C, et al. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. *American Journal of Pathology* 1998; 153(3): 973-83.

Lee JH, et al. Expression of a splice variant of KAI1, a tumor metastasis suppressor gene, influences tumor invasion and progression. *Cancer Research* 2003; 63(21): 7247-55.

Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987; 235(4785): 177-82.

Thor AD, et al. Activation (tyrosine phosphorylation) of erbB2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. *Journal of Clinical Oncology* 2000; 18(18): 3230-9.

Wang S, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. *Modern Pathology* 2002; 15(2): 137-145.

Wilson KS, et al. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. *American Journal of Pathology* 2002; 161(4): 1171-85.

Yanez-Mo M, et al. Tetraspanins in intercellular adhesion of polarized epithelial cells: spatial and functional relationship to integrins and cadherins. *Journal of Cell Science* 114: 577-87.

Yang X, et al. KAI1 protein is down-regulated during the progression of human breast cancer. *Clinical Cancer Research* 2000; 6: 3424-9.

Yang X, et al. Overexpression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells. *Cancer Research* 2001; 61(13): 5284-8.

## APPENDICES

### Appendix 1.

American Association for Cancer Research (AACR) Special Conference  
"Advances in Breast Cancer Research: Genetics, Biology, and Clinical Implications"  
October 8-12, 2003  
Hyatt Regency Huntington Beach Resort and Spa, Huntington Beach, California

## ABSTRACT

Introduction The purpose of this study was to test the hypothesis that the tetraspanin metastasis genes, *KAI1/CD82* and *CO-029*, are downstream effectors of the receptor tyrosine kinase, HER2, in breast cancer cells that have gene amplification of *HER-2/neu*. Women with breast tumors that have gene amplification of *HER-2/neu* suffer from early metastatic relapse and shortened survival times. The mechanisms by which HER2 overexpression confer increased metastatic potential are unclear. The tetraspanin family consists of 30 genes, some of which are central to co-stimulation, signal transduction, and cell fusion (between egg and sperm, myotubules, syncytium formation, etc.). Three tetraspanin members, *CD9*, *CD63*, and *CD82/KAI1*, are metastasis suppressor genes, as proven by their ability to inhibit metastasis in animal models. Only one tetraspanin, *CO-029*, seems to promote metastasis *in vivo*. The products of these genes are cell surface proteins that modulate cellular adhesion, invasion, and motility, three core characteristics of metastatic cells. Our aim was to define a molecular link between *HER-2/neu* and metastasis in breast cancer patients.

Experimental Procedures 1. Gene expression profiling was used to study regulated genes in HER2 positive vs. HER2 negative primary breast tumors. 2. Hamon Cancer Center (HCC) breast cancer cell lines were used as a model system to validate the microarray data. We studied protein expression of HER2, *KAI1*, and *CO-029* by immunoblot techniques using monoclonal antibodies. 3. We analyzed protein expression of the three antigens by immunohistochemistry (IHC) in archival tumor blocks that corresponded to the cell lines. 4. We used transfection experiments to ask whether HER2 could alter tetraspanin gene expression. 5. Finally, we used RNA interference (RNAi) to study the effects of downregulation of HER2 on tetraspanin expression.

Results 1. In a microarray experiment, *KAI1* was the third most downregulated gene among 5,500 genes and ESTs in HER2 positive vs. HER2 negative tumors. *KAI1* expression was 15-fold lower in HER2 positive vs. HER2 negative breast cancers ( $p<0.01$ ). 2. Gene amplification of *HER-2/neu* was associated with relatively low *KAI1* expression in three HER2 positive vs. four HER2 negative cell lines ( $p<0.05$ ). 3. For each cell line, we retrieved the correspondent tumor block and used IHC to show that HER2 expression was inversely correlated with *KAI1* expression ( $p<0.04$ ). Therefore, the relationship between HER2 and *KAI1* expression was not an *in vitro* artifact. 4. In transfection studies, we ectopically expressed HER-2/neu in MCF-7 breast cancer cells and demonstrated that overexpression of HER2 resulted in loss of expression of *KAI1*, but increased expression of *CO-029* (4.4-fold;  $p=0.03$ ). 5. Finally, we knocked down expression of *HER-2/neu* by RNAi and demonstrated that *KAI1* levels increased four-fold ( $p=0.05$ ).

Conclusions Gene amplification of *HER-2/neu* results in downregulation of the metastasis suppressor, *KAII*, and the up-regulation of the metastasis promoter, *CO-029*. This novel mechanism may explain, in part, why women with gene amplification of *HER-2/neu* in their breast tumors are at high risk for metastasis and early death. Furthermore, this is the first demonstration of a receptor tyrosine kinase (RTK) that regulates tetraspanin metastasis genes, which may signify a new paradigm that links RTK oncogenes to metastasis genes.

Appendix 2.

**CURRICULUM VITAE**

**Name** Donald Paul Lombardi, M.D.

**Address**  
Mailing Address:  
Washington University School of Medicine  
Division of Oncology, Campus Box 8069  
660 South Euclid Avenue  
St. Louis, Missouri 63110

Laboratory and Overnight Shipping Address:

Washington University School of Medicine  
McDonnell Medical Sciences Building  
Room 558  
4566 Scott Avenue  
St. Louis, MO 63110

Home

5 Ridge Line Drive  
St. Louis, Missouri 63122

**Telephone**  
Work 314.362.4796  
Laboratory 314.362.8967  
Pager 314.508.4344  
Facsimile 314.747.2797

**E-mail** Donald.Lombardi@im.wustl.edu

**Birth Date** May 30, 1960

**Birthplace** Boston, Massachusetts

**Citizenship** United States of America

**Education**

1982-1986 M.D. University of Rochester School of Medicine  
Rochester, New York

1978-1982 A.B. Bowdoin College  
Brunswick, Maine  
*Magna cum laude*  
High Honors in Biochemistry Senior Thesis

### **Education (continued)**

### (Independent Laboratory Research Study)

## Board Certification

2003 Medical Oncology, Re-certification  
1991 Medical Oncology  
1989 American Board of Internal Medicine

## Medical Licensure

2004-present	Missouri
1999-present	Texas
1996-2000	North Carolina
1995	Tennessee, Virginia, Montana, and Oregon
1991	Washington, D. C.

## **Employment/Fellowships/Residency/Internship/Research**

2004-present Washington University School of Medicine  
Division of Oncology  
Section of Medical Oncology  
Department of Medicine  
Siteman Cancer Center

1999-2004 University of Texas Southwestern Medical Center  
Assistant Professor of Internal Medicine  
Division of Hematology-Oncology  
Department of Internal Medicine  
Member, Simmons Cancer Center

Principal Investigator  
Hamon Center for Therapeutic Oncology Research  
Attending Physician  
Parkland Memorial Hospital  
Zale-Lipshy University Hospital  
St. Paul University Hospital

1998-1999 The University of North Carolina at Chapel Hill  
Research Assistant Professor

### **Employment/Training (continued)**

1996-1999	Duke University Medical Center National Institute of Environmental Health Sciences
1996-1999	The University of North Carolina at Chapel Hill Training Program for Physicians in Environmental Clinical Sciences
1996-1999	National Institute of Environmental Health Sciences Postdoctoral fellowship in Molecular Biology in the Laboratory of J. Carl Barrett, Ph.D., Scientific Director, NIEHS Currently, Director, Center for Cancer Research National Cancer Institute
1996-1999	UNC Hospitals Clinical Instructor Division of Hematology/Oncology
1995-1996	Locum Tenens in Medical Oncology Cancer Carepoint, Inc. Medical Doctor Associates, Inc. in Tennessee, Virginia, Montana, Oregon
1994-1996	Sibley Memorial Hospital Washington, D.C. Hospitalist (Internal Medicine)
1992-1994	National Cancer Institute Biotechnology Fellow in Molecular Genetics Laboratory of Ilan R. Kirsch, M.D., currently Head, Genetics Branch Center for Cancer Research National Cancer Institute
1992-1994	NCI/Navy Medical Oncology Branch Senior Clinical Fellow/ Assistant Attending Physician
1990-1992	National Cancer Institute (NCI) Postdoctoral Fellow in Molecular Genetics Laboratory of Ilan R. Kirsch, M.D.
1989 - 1992	National Institutes of Health National Cancer Institute

## **Training (continued)**

**Medicine Branch**  
**Medical Staff Fellow in Medical Oncology**

**Chairmen:**  
Charles E. Myers, M.D., formerly  
Director  
University of Virginia Cancer Center

Robert E. Wittes, M.D., currently,  
Physician-in-Chief  
Memorial Hospital  
Memorial Sloan-Kettering Cancer Center

Carmen J. Allegra, M.D., formerly,  
Chairman, Medicine Branch  
National Cancer Institute

**Trained Under:**  
Bruce A. Chabner, M.D.  
Director, Division of Cancer Treatment, NCI  
Currently, Clinical Director and  
Chief, Division of Hematology and Oncology  
Massachusetts General Hospital Cancer Center

1986 - 1989	University of Michigan Hospital Department of Internal Medicine Residency Internship  Department of Internal Medicine Chairman: William N. Kelley, M.D., formerly CEO and Dean University of Pennsylvania School of Medicine
1980-1984	Harvard Medical School Department of Microbiology and Molecular Genetics Summer Research Student in Laboratory of Harold Amos, Ph.D.,

## **Professional Societies**

American Association for Cancer Research  
American Cancer Society  
American Society of Clinical Oncology  
Society for Molecular Imaging

## **Honors and Awards**

2002	Physician-Scientist Training Award Department of Defense U.S. Army Medical Research and Materiel Command Breast Cancer Research Program
2000	Developmental Project/Career Development Award University of Texas SPORE in Lung Cancer
1998	Clinical Associate Physician (CAP) Award A Career Development Award National Institutes of Health University of North Carolina at Chapel Hill
1989	House Officer Research Award University of Michigan Medical School Department of Internal Medicine First place among 40 3 <sup>rd</sup> -year House Officers “Anaerobic bacteremia: incidence, patient characteristics, and clinical significance”
1987	Golden Beeper Award Award for Excellence in the Teaching of Medical Students Internship Year University of Michigan Medical School
1985	Lange Medical Publications Student Award Award for development of new curriculum University of Rochester School of Medicine
1982	Colonel William Henry Owen Premius Award for leadership in the Chapel Program Bowdoin College
1980 Summer	Alvan T. and Viola D. Fuller Summer Student Undergraduate Research Fellow

## **Honors and Awards (continued)**

	American Cancer Society Harvard Medical School
1978-1982	James Bowdoin Scholar Equivalent to Dean's List Bowdoin College
1978	Student Leader of the Year at Wilmington High School The Golden Scroll for Scholastic Achievement American Academy of Achievement, California
<b>Reviewer</b>	Ad-hoc For Cancer Research, Oncogene, Clinical Cancer Research Endocrine-Related Cancers
<b>Committees</b>	
2002-2004	Physician Liaison, Subcommittee on Quality Cancer Care, UT Southwestern Medical Center
	Chairman, Subcommittee on Preparation for American College of Surgeons Survey Parkland Memorial Hospital Cancer Program Result: Certification Approved for a full 3-year accreditation #1 rating
	Member, Zale-Parkland Cancer Committees UT Southwestern Medical Center
1999-2004	American Cancer Society Texas Division/Prostate Cancer Committee Chairman, Research Subcommittee
<b>Grant Support</b>	
1. Current	
Source	Department of Defense/U.S. Army Medical Research
Type	Physician-Scientist Training Award

### **Grant Support (continued)**

Title	The Metastasis Suppressor Gene, <i>KAII/CD82</i> , and the Proto-oncogene, <i>HER-2/neu</i> , as Molecular Determinants of Metastasis in Breast Cancer Patients
Dates	07/21/03 - 07/20/08
% Of time allocated	70%
Award	\$371,916

## 2. Past

Source	National Institutes of Health
Type	Developmental Project/Career Development Award
Title	University of Texas SPORE in Lung Cancer The Metastasis Suppressor Genes <i>KAII</i> and <i>MRP-1</i> in Lung Cancer
Grant number	P50 CA70907
Dates	02/01/00 – 08/01/00
% Of time allocated	5%
Award	\$25,000, direct costs

### 3. Past

Source: National Institutes of Health  
Type: Clinical Associate Physician (CAP) Award  
Grant number: 3 MO1 RR00046-3852  
Dates: 07/01/98 - 06/30/99  
% Of time allocated: 80%  
Award: \$95, 153

## BIBLIOGRAPHY

Mandel, Kenneth G., Lively, Mary K., Lombardi, Donald, and Amos, Harold. Reactivation of NAD (H) biosynthetic pathway by exogenous NAD<sup>+</sup> in Nil cells severely depleted of NAD(H). *Journal of Cellular Physiology* 114: 235-244, 1983.

Aplan, Peter D., Lombardi, Donald P., Ginsberg, Ann M., Cossman, Jeffrey, Bertness, Virginia L. , and Kirsch, Ilan R. Disruption of the human *SCL* locus by "Illegitimate" V-(D)-J recombinase activity. *Science* 250: 1426-9, 1990.

Aplan, Peter D., Lombardi, Donald P., Kirsch, Ilan R. Structural characterization of *SIL*, a gene frequently disrupted in T-cell acute lymphoblastic leukemia. *Molecular and Cellular Biology* 11(11): 5462-9, 1991.

Foss, RD, Laskin, WB, Lombardi, DP, Morton, AL, Snyder, J. Anaplastic large cell lymphomas. Head & Neck 13: 545-48, 1991.

## BIBLIOGRAPHY (continued)

Lombardi, Donald, Engleberg, N. Cary. Anaerobic bacteremia: incidence, patient characteristics, and clinical significance. *American Journal of Medicine* 92: 53-60, 1992.

Aplan, PD, Lombardi, DP, Reaman, GH, Sather, H, Hammond, D, Kirsch, IR. Involvement of the putative hematopoietic transcription factor *SCL* in T-cell acute lymphoblastic leukemia. *Blood* 79(5): 1327-33, 1992.

Kirsch, IR, Abdallah, JM, Bertness, VL, Hale, M, Lipkowitz, S, Lista, F, Lombardi, DP. Lymphocyte-specific genetic instability and cancer. *Cold Spring Harbor Symposia on Quantitative Biology, Volume LIX, The Molecular Genetics of Cancer*, The Cold Spring Harbor Laboratory Press, pp. 287-95, 1994.

Abdallah, JM, Lombardi, DP, Kirsch, IR. Genetic instability in patients with Hodgkin's Disease undergoing chemotherapy. *Journal of Clinical Investigation* 96: 2744-7, 1995.

Geradts, Joseph, Maynard, Robert, Birrer, Michael J., Hendricks, Denver, Abbondanzo, Susan L., Fong, Kwun M., Barrett, J. Carl, Lombardi, Donald P. Frequent loss of *KAI1* expression in squamous and lymphoid neoplasms: an immunohistochemical study of archival tissues. *American Journal of Pathology*, 154(6): 1665-71, 1999.

Lombardi, Donald P., Geradts, Joseph, Foley, Julie F., Chiao, Chia, Lamb, Pattie W., Barrett, J. Carl. Loss of *KAI1* expression in the progression of colorectal cancer. *Cancer Research*, 59(22): 5724-31, 1999.

Garry, Vincent F., Tarone, Robert E., Kirsch, Ilan R., Abdallah, Jorge M., Lombardi, Donald P., Long, Leslie K., Burroughs, Barbara L., Barr, Dana B., and Kesner, James S. Biomarker correlations of urinary 2,4-D levels in foresters: genomic instability and endocrine disruption. *Environmental Health Perspectives*, 109(5): 495-500, 2001.

Li, Yingming, Okegawa, Takasugu, Lombardi, Donald P., Frenkel, Eugene P., and Hsieh, Jer-Tsong. Enhanced transgene expression in androgen-independent prostate cancer gene therapy by taxane chemotherapeutic agents. *Journal of Urology* 167 (1): 339-346, 2002.

### Invited Preview

Crowder, Robert J, Lombardi, Donald P., and Ellis, Matthew J. Successful targeting of ErbB2 receptors—is PTEN the key? Preview; *Cancer Cell* 6(2): 103-4, 2004.